More recent ASCO guidelines have expanded to recommend tumor testing for mutations in KRAS exons 3 (codons 59 and 61) and 4 (codons 117 and 146) as findings from recent Phase II and III trials indicated patients with these mutations also will not benefit from anti-EGFR therapy [7]. Here, EGFR is linked to neoplasm.